Nevro Corp (NVRO) Price & Analysis

Compare

209 Followers

NVRO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.17 - $13.84

Previous CloseN/A

Volume192.24K

Average Volume (3M)N/A

Market Cap

$224.09M

Enterprise Value$98.88M

Total Cash (Recent Filing)$30.61M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Apr 30, 2025

EPS Estimate

-0.82

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.05

Shares Outstanding31,007,000

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)1.06

Price to Sales (P/S)0.54

P/FCF Ratio2.90

Enterprise Value/Market Cap0.44

Enterprise Value/Revenue0.24

Enterprise Value/Gross Profit0.37

Enterprise Value/Ebitda-1.39

Forecast

1Y Price Target

$5.85

Price Target Upside0.17% Upside

Rating ConsensusHold

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

AcquisitionNevro Corp announced an agreement to be acquired by GMED for $5.85/share, which represents a 17% premium to its undisturbed closing price.

Financial PerformanceQ4 preliminary results ahead of consensus: NVRO announced that it expects Q4/24 revenue in the range of $105M-$106M, ahead of our $98.6M estimate and the Street’s $100.2M.

SynergiesGMED sees potential revenue synergies by leveraging its position with spine and neurosurgeons to grow the spinal cord stimulation business.

Bears Say

CompetitionNevro Corp had a large downward revision to guidance due to increased competition and physicians choosing companies with a broader spectrum of products.

Market ChallengesThere are ongoing challenges in the spinal cord stimulation market, including increased competitive dynamics and market softness.

Revenue HeadwindsRevenue headwinds expected to persist into 2025 with NVRO citing competition/new product trialing as well as changes to commercial team and optimization of sales territories.

Nevro Corp News

NVRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Nevro Corp (NVRO) is scheduled to report 1st quarter earnings on 04/30/2025. Regarding Q1 estimates, Wall Street analysts...

3M ago

NVRO

Nevro Corp Completes Merger and Delists from NYSE

Nevro Corp ( ($NVRO) ) has provided an announcement. On April 3, 2025, Nevro Corp, a company involved...

4M ago

NVRO

Globus Medical completes acquisition of Nevro

Globus Medical (GMED) announced the completion of its previously disclosed acquisition of Nevro (NVRO). The acquisition of Nevro...

4M ago

GMED

NVRO

Nevro Corp. Reports 2024 Financial Results Amid Acquisition News

Nevro Corp ( ($NVRO) ) has released its Q4 earnings. Here is a breakdown of the information Nevro...

5M ago

NVRO

Nevro reports Q4 EPS ($1.41), consensus (75c)

Reports Q4 revenue $105.5M, consensus $102.61M. Cash, cash equivalents and short-term investments totaled $292.5M as of December 31,...

5M ago

NVRO

Nevro is not issuing FY25 guidance

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is...

5M ago

NVRO

NVRO Upcoming Earnings Report: What to Expect?

Nevro Corp (NVRO) is scheduled to report 4th quarter earnings on 03/04/2025, after the market closes. Regarding Q4...

5M ago

NVRO

Globus Medical price target lowered to $93 from $95 at Wells Fargo

Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95...

6M ago

GMED

NVRO

Nevro upgraded to Hold from Underperform at Jefferies

Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after...

6M ago

NVRO

Nevro price target raised to $5.85 from $5 at Baird

Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating...

6M ago

GMED

NVRO

Nevro price target raised to $5.85 from $4 at Canaccord

Canaccord raised the firm’s price target on Nevro (NVRO) to $5.85 from $4 and keeps a Hold rating...

6M ago

GMED

NVRO

Nevro upgraded to Neutral from Underweight at Piper Sandler

Piper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85,...

6M ago

NVRO

Nevro Corp Announces Merger Agreement with Globus Medical

Nevro Corp ( ($NVRO) ) has issued an announcement. Nevro Corp. has entered into a merger agreement with...

6M ago

NVRO

Globus acquisition of Nevro ‘fairly low-risk bet,’ says BTIG

BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not...

6M ago

GMED

NVRO

NVRO FAQ

What was Nevro Corp’s price range in the past 12 months?

Nevro Corp lowest stock price was $3.17 and its highest was $13.84 in the past 12 months.

What is Nevro Corp’s market cap?

Nevro Corp’s market cap is $224.09M.

When is Nevro Corp’s upcoming earnings report date?

Nevro Corp’s upcoming earnings report date is Apr 30, 2025 which is 101 days ago.

How were Nevro Corp’s earnings last quarter?

Currently, no data Available

Is Nevro Corp overvalued?

According to Wall Street analysts Nevro Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nevro Corp pay dividends?

Nevro Corp does not currently pay dividends.

What is Nevro Corp’s EPS estimate?

Nevro Corp’s EPS estimate is -0.82.

How many shares outstanding does Nevro Corp have?

Nevro Corp has 31,007,000 shares outstanding.

What happened to Nevro Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nevro Corp?

Currently, no hedge funds are holding shares in NVRO

Nevro Corp Stock Smart Score

Underperform

Fundamentals

Return on Equity

-43.28%

Trailing 12-Months

Asset Growth

-12.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nevro Corp

Nevro Corp (NVRO) is a global medical device company that specializes in developing and commercializing innovative solutions for the treatment of chronic pain. The company's flagship product is the Senza spinal cord stimulation (SCS) system, which is designed to deliver high-frequency stimulation to the spinal cord to alleviate pain. Nevro operates primarily within the healthcare and medical device sectors, focusing on improving patient outcomes through advanced technology.

Nevro Corp (NVRO) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

NVRO Stock 12 Month Forecast

Average Price Target

$5.85

▲(0.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Dec<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.72,5.7299999999999995,5.739999999999999,5.75,5.76,5.77,5.779999999999999,5.79,5.8,5.81,5.819999999999999,5.83,5.84,{"y":5.85,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.72,5.7299999999999995,5.739999999999999,5.75,5.76,5.77,5.779999999999999,5.79,5.8,5.81,5.819999999999999,5.83,5.84,{"y":5.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.72,5.7299999999999995,5.739999999999999,5.75,5.76,5.77,5.779999999999999,5.79,5.8,5.81,5.819999999999999,5.83,5.84,{"y":5.85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.76,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.22,"date":1706745600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.32,"date":1711929600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.41,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1717200000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.18,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.23,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.53,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.27,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.72,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Similar Stocks

ABT

Abbott Laboratories

―

BSX

Boston Scientific

―

MDT

Medtronic

―

SYK